New OCCIDENT Website
Having sharpened our investor profile and revised our communication, we get to the point: OCCIDENT – The Science Investor.
News
Follow-on investment in hemotune
Successful closing of the CHF 14 million Series B2 of hemotune under the lead of Belmondo and with the participation of OCCIDENT, as well as existing and new investors.
Resistell is publishing in Nature!
A peer-reviewed article on Resistell's rapid phenotypic solution for antibiotic susceptibility testing (AST) has been published in Nature Communications.
Follow-on investment in Tubulis
OCCIDENT is excited to announce its participation in Tubulis' €128 million Series B2 round co-led by EQT Life Sciences and Nextech Invest.
Celebrating 10 years of Sandra at OCCIDENT
Especially in the venture capital business, 10 years are quite a long time, full of changes and many new developments – both externally and internally at OCCIDENT.
Initial Investment in Altavo
OCCIDENT is taking the lead in the oversubscribed €5 million Series A round of this Dresden-based MedTech start-up.
Initial Investment in Chipmetrics
OCCIDENT invests in the Finnish company Chipmetrics, which sets a new standard for the semiconductor industry by developing and manufacturing innovative metrology chips and wafers.
OCCIDENT and CO-OPERAID enable “Talents”
Again this year, on the occasion of the International Day of Education on January 24, we look back together with CO-OPERAID on a successful year of CO-OPERAID’s “Talents” program.
Welcome to the OCCIDENT Team, Paul!
Paul will support our Life Sciences Team in Munich as Junior Investment Manager.